Skip to content

US · JAZZ · BIOTECHNOLOGY

Jazz Pharmaceuticals plc (JAZZ) intrinsic value and stock valuation

$230.26as of 2026-11-21 · Mkt cap 16.43B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jazz Pharmaceuticals plc DCF and intrinsic value

InvestorsCraft values JAZZ with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from JAZZ’s statements →

Jazz Pharmaceuticals plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dublin, DU D04 E5W7 jazzpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$4.27B+12.5% 5y CAGRd
20112025
Net income
-$-356.15M
20112025
Free cash flow
$1.15B+17.1% 5y CAGRd
20112025
Total equity
$4.32B+3.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B
Operating income$224.4M$716.6M$578.6M-$-65.53M$170.3M
Net income-$-356.15M$560.1M$414.8M-$-224.06M-$-328.95M
EPSd-$-5.84M$8.49M$5.76M-$-3.58M-$-5.51M
Operating cash flow$1.36B$1.4B$1.09B$1.27B$778.5M
Capital expenditure-$-209.75M-$-48.07M-$-23.96M-$-498.19M-$-45.53M
Free cash flow$1.15B$1.35B$1.07B$773.8M$733M
Total assets$11.7B$12B$11.4B$10.8B$12.3B
Total debt$5.42B$6.16B$5.79B$5.81B$6.15B
Net debt$4.03B$3.75B$4.29B$4.93B$5.56B
Total equity$4.32B$4.09B$3.74B$3.09B$3.97B
Cash and short-term investments$2.44B$2.99B$1.63B$881.5M$591.5M
Income statement
20252024202320222021
Revenue$4.27B$4.07B$3.83B$3.66B$3.09B
Cost of revenue$503.3M$445.7M$435.6M$540.5M$440.8M
Gross profit$3.76B$3.62B$3.4B$3.12B$2.65B
Research and development expenses$782.7M$884M$849.7M$590.5M$505.8M
Selling, general and administrative expenses$1.81B$1.39B$1.34B$1.42B$1.45B
Other expenses$947.9M$637.3M$627.3M$1.18B$525.8M
Operating expenses$3.54B$2.91B$2.82B$3.18B$2.48B
Cost and expenses$4.04B$3.35B$3.26B$3.72B$2.92B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$195.1M$238.1M$289.4M$288.2M$278.8M
Depreciation and amortization$542M$660.1M$638.7M$629.5M$552.5M
Ebitda$108.5M$1.52B$1.45B$1.47B$1.03B
Operating income$224.4M$716.6M$578.6M-$-65.53M$170.3M
Total other income/expenses, net-$-853.01M-$-247.94M-$-283.66M-$-317.18M-$-283.83M
Income before tax-$-628.59M$468.7M$294.9M-$-382.7M-$-113.55M
Income tax expense-$-272.44M-$-91.43M-$-119.91M-$-158.65M$216.1M
Net income-$-356.15M$560.1M$414.8M-$-224.06M-$-328.95M
Weighted average shares outstanding$61M$61.8M$63.3M$62.5M$59.7M
Weighted average diluted shares outstanding$61M$66M$72.1M$62.5M$59.7M
Balance sheet
20252024202320222021
Cash and short-term investments$2.44B$2.99B$1.63B$881.5M$591.5M
Net receivables$830.8M$716.8M$705.8M$651.5M$563.4M
Inventory$417M$480.4M$597M$714.1M$1.07B
Total current assets$4.17B$4.63B$3.44B$2.61B$2.61B
Property, plant and equipment, net$258.7M$227M$235M$301.4M$343.4M
Goodwill and intangible assets$6.26B$6.47B$7.17B$7.49B$8.98B
Long-term investments$4.3M$4.33M$0.00$5.5M$5M
Total non-current assets$7.49B$7.38B$7.96B$8.23B$9.69B
Total assets$11.7B$12B$11.4B$10.8B$12.3B
Accounts payable$122.1M$77.9M$102.8M$90.8M$100.3M
Short-term debt$1.04B$45.8M$624.4M$46.9M$46.8M
Deferred revenue$0.00$0.00$0.00$460K$2.09M
Total current liabilities$2.24B$1.04B$1.54B$933.2M$809.3M
Long-term debt$4.38B$6.12B$5.17B$5.77B$6.11B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$460K
Total non-current liabilities$5.1B$6.88B$6.12B$6.82B$7.52B
Capital lease obligations$65.6M$53.7M$78.7M$87.8M$103M
Total liabilities$7.34B$7.92B$7.66B$7.75B$8.33B
Common stock$10K$60K$60K$60K$60K
Retained earnings$646.2M$1.13B$878.7M$733.6M$830.2M
Accumulated other comprehensive income (loss)-$-568.6M-$-947.67M-$-842.15M-$-1.13B-$-400.36M
Total equity$4.32B$4.09B$3.74B$3.09B$3.97B
Total investments$1.05B$584.3M$120M$5.5M$5M
Total debt$5.42B$6.16B$5.79B$5.81B$6.15B
Net debt$4.03B$3.75B$4.29B$4.93B$5.56B
Cash flow statement
20252024202320222021
Net income-$-356.15M$560.1M$414.8M-$-224.06M-$-329.67M
Depreciation and amortization$696.3M$660.1M$638.7M$629.5M$552.5M
Stock-based compensation$291.1M$248M$226.8M$222M$189M
Change in working capital$18.9M-$-76.72M-$-204.44M$9.9M-$-47.95M
Accounts receivable-$-106.28M-$-21.11M-$-51.88M-$-90.14M-$-92.73M
Inventory-$-86.04M-$-45.54M-$-13.42M-$-49.64M-$-48.86M
Accounts payable$39.9M-$-20.07M$9.6M-$-11.22M$57M
Net cash provided by operating activities$1.36B$1.4B$1.09B$1.27B$778.5M
Investments in property, plant and equipment-$-58.75M-$-38.07M-$-23.96M-$-498.19M-$-27.64M
Acquisitions, net-$-858.05M$0.00$0.00$53M-$-6.23B
Net cash used for investing activities-$-1.51B-$-508.19M-$-163.06M-$-446.23M-$-5.21B
Common stock issued$107.9M$20.7M$46.5M$0.00$135.3M
Common stock repurchased-$-125.02M-$-311.43M-$-269.76M-$-50K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-873.38M$20.5M-$-305.25M-$-529.49M$3.97B
Net change in cash-$-1.02B$906.6M$624.8M$290M-$-466.32M
Cash at end of period$1.39B$2.41B$1.51B$881.5M$591.5M
Operating cash flow$1.36B$1.4B$1.09B$1.27B$778.5M
Capital expenditure-$-209.75M-$-48.07M-$-23.96M-$-498.19M-$-45.53M
Free cash flow$1.15B$1.35B$1.07B$773.8M$733M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jazz Pharmaceuticals plc

        Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

        CEO
        Renee D. Gala
        Employees
        2.89K
        Beta
        0.32

        Explore

        Frequently asked questions

        What is the intrinsic value of Jazz Pharmaceuticals plc (JAZZ)?

        Jazz Pharmaceuticals plc (JAZZ) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is JAZZ undervalued?

        JAZZ trades at a price of $230.26 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.